Ontology highlight
ABSTRACT: Background and objectives
Recent studies demonstrating decreased survival following minimally invasive surgery (MIS) for cervical cancer have generated concern regarding oncologic efficacy of MIS. Our objective was to evaluate the association between surgical approach and 5-year survival following resection of abdominopelvic malignancies.Methods
Patients with stage I or II adenocarcinoma of the prostate, colon, rectum, and stage IA2 or IB1 cervical cancer from 2010-2015 were identified from the National Cancer Data Base. The association between surgical approach and 5-year survival was assessed using propensity-score-matched cohorts. Distributions were compared using logistic regression. Hazard ratio for death was estimated using Cox proportional-hazard models.Results
The rate of deaths at 5 years was 3.4% following radical prostatectomy, 22.9% following colectomy, 18.6% following proctectomy, and 6.8% following radical hysterectomy. Open surgery was associated with worse survival following radical prostatectomy (HR, 1.18; 95% CI, 1.05-1.33; P?=?.005), colectomy (HR, 1.45; 95% CI, 1.39-1.51; P?ConclusionsThese results suggest that MIS is an acceptable approach in selected patients with prostate, colon, and rectal cancers, while concerns regarding MIS resection of cervical cancer appear warranted.
SUBMITTER: Yuce TK
PROVIDER: S-EPMC7755029 | biostudies-literature | 2020 Mar
REPOSITORIES: biostudies-literature
Yuce Tarik K TK Ellis Ryan J RJ Chung Jeanette J Merkow Ryan P RP Yang Anthony D AD Soper Nathaniel J NJ Tanner Edward J EJ Schaeffer Edward M EM Bilimoria Karl Y KY Auffenberg Gregory B GB
Journal of surgical oncology 20200122 4
<h4>Background and objectives</h4>Recent studies demonstrating decreased survival following minimally invasive surgery (MIS) for cervical cancer have generated concern regarding oncologic efficacy of MIS. Our objective was to evaluate the association between surgical approach and 5-year survival following resection of abdominopelvic malignancies.<h4>Methods</h4>Patients with stage I or II adenocarcinoma of the prostate, colon, rectum, and stage IA2 or IB1 cervical cancer from 2010-2015 were iden ...[more]